MOA also validates Brilacidin, IMO
The clinical results are consistent with preclinical animal studies in which SGX942 reduced duration of oral mucositis by approximately 50% following either chemotherapy or radiation therapy."
"We are extremely pleased with the findings from the first Phase 2 study of SGX942. The study met all of its objectives of defining the best dose, the most appropriate clinical endpoint, and patient population to use in future pivotal trials," stated Richard Straube, MD, Senior Vice President and Chief Medical Officer of Soligenix. "The positive and clinically meaningful effect observed on the duration of ulcerative and severe oral mucositis clearly demonstrates the significant biologic activity that SGX942 exerts on this catastrophic side-effect of cancer treatment. The impact of SGX942 on other clinically beneficial outcomes (e.g., tumor control and infection rates) confirms the animal model data that, in treating patients' oral mucositis, SGX942 may also prove to have a positive impact on their head and neck cancer.
SGX942 is an innate defense regulator (IDR), a new class of short, synthetic peptides. It has a novel mechanism of action in that it modulates the body's reaction to both injury and infection towards an anti-inflammatory and an anti-infective response. IDRs have no direct antibiotic activity but, by modulating the host's innate immune system responses, increase survival after infections with a broad range of bacterial Gram-negative and Gram-positive pathogens. It also accelerates resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- and/or radiation therapy."
Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
The results are, however, not as good as what I expect from BOM. Tempus fugit, I'm glad Leo is pushing forward hard and fast.
If Mr. Bite’s constant complaining was that CTIX is a lab rat for bigger firms, who watch from the sidelines as all small Bio's spend money on R&D, test the market and work out the bugs, thus paving the way for the big boys to roll right over them, I'd have some sympathy for his constant whining. But his personal vendetta against Leo is merely irrelevant.
TPIV is run as a piggybank for the four over paid exec's that run the company, buyer beware. This business is difficult enough without having to hope management leaves a few scraps for investors.
Mako the shark presumes to trump MD Anderson as well:
MD Anderson to Test Cellceutix Candidate Against Lymphoma, Multiple Myeloma
Emerging biopharmaceutical firm Cellceutix has inked a material transfer agreement (MTA) with the University of Texas MD Anderson Cancer Center, through which the firm will provide MD Anderson with its anticancer drug candidate Kevetrin™ (thioureidobutyronitrile) for evaluation of the compound as a potential new treatment for lymphoma and multiple myeloma.
MD Anderson is planning to use in vivo and in vitro methods to investigate specific pathways, gene expression, mechanism of action, and apoptotic activity of Kevetrin in a range of concentrations and time points in both mutant and wild-type p53 myeloma and lymphoma cell lines. Studies are also planned to evaluate Kevetrin against models of multiple myeloma cell lines that are resistant to bortezomib, lenalidomide, and other FDA-approved chemotherapies. Additional studies will be conducted evaluating the antitumor activity of Kevetrin when used as a combination therapy with several FDA-approved drugs. MD Anderson will provide funding for these studies of Kevetrin defined by the MTA."
agree, the VWAP today was $1.61 , they waited til late day for light volume to walk it down, this will be a slow week anything can happen. Need some good data to up list and leave pink sheets behind.
Shawn Langlois (MarketWatch) has a lesson for traders about a rookie who did not accurately assess his risk. He held an overnight short position in KBIO that was supposedly going bankrupt. The next morning he learned that his $37,000 account was wiped out and he owed his broker over $100,000. I suspect this is a similar risk some on this board are running.
I's advise that when you’re in a hole U stop digging. I did some tax loss selling today, moved the money to an equal opportunity and saved the tax, some of us actually make money at this and taxes are a real consederation. I'm not going to respond to you again as its an obvious waste of my time, please don't mistake that for rolling over, I actually know what I'm talking about.
You’re speaking above your pay grade, lots of people move money from one stock to another to limit the nearly 40% tax, for them tax minimization amounts to a lot of money.
I just checked Rosens web site and thier list of Securities Class Action cases and apparently nothing because CTIX is not listed.
A six month daily chart shows CTIX stock was just over $3.50 a couple weeks before the hit piece and law suit, it dropped almost every day as they were likely shorting heavily before publishing on SA. Some here have said the suit has been removed from Rosen's website where it previously existed as late as last week. Since the suit was based entirely on the article and probably coordinated, it stands to reason that the share price should recover to at least the level it was at prior too, and maybe higher if they have not all covered, I assume most have. Still it's an easy double from here as the company has had nothing but positive news and up listing looks more and more likely. If the suit is officially withdrawn that negates the article and the stock very looks cheap.
U.S. regulators are reviewing whether to make short sellers step out of the shadows, as negative comments by research firms increasingly batter share prices.
“It’s a complex sort of landscape, but it is an issue that has our intense attention,” Securities and Exchange Commission Chair Mary Jo White said during an interview on Bloomberg Television on Tuesday in response to a question about whether the agency would consider rules requiring short-selling disclosures by investors. She declined to discuss specific companies.
Drugmaker Mallinckrodt Plc shares fell 17 percent Monday after it was criticized on Twitter by Citron Research, a stock commentary site led by short seller Andrew Left. Last month, Citron sparked a rout of Valeant Pharmaceuticals International Inc.
The SEC requires hedge funds to report their long positions periodically, but it has no such rule for their short positions, or those that bet against stocks. In Europe, hedge funds have had to disclose individual shorts of as little as 0.2 percent of a company’s market value to their national regulator since 2012. They have to publicly disclose shorts that total 0.5 percent.
“Short selling has a legitimate, positive purpose in the marketplace,” White said. “That’s very different, though, than if you manipulate by short selling.”
More disclosure wouldn’t necessarily affect short sellers like Citron’s Left, who makes his bearish views of companies public. Mallinckrodt has “significantly more downside” than Valeant, Citron said in a Twitter posting on Monday. The firm had previously accused Valeant of inflating sales using specialty pharmacies such as Philidor RX Services. From 2010, Valeant shares rose more than 10-fold to peak in August. Since then, they have lost 67 percent of their value as of Monday’s close.
White said Twitter is an information source that must be policed actively, and a 140-character Twitter posting and a four-hour presentation are essentially the same.
The SEC has .....